What is Voquezna Made Of?
Voquezna, also known as Vonoprazan, is a potassium-competitive acid blocker used to treat erosive esophagitis and as part of a treatment regimen for Helicobacter pylori infection [1]. Its active pharmaceutical ingredient is vonoprazan [1].
How Does Vonoprazan Work?
Vonoprazan works by reversibly inhibiting the activity of the H+/K+-ATPase enzyme in gastric parietal cells. This enzyme is responsible for the final step of acid secretion. By blocking this pump, vonoprazan reduces gastric acid production [1].
When Does Voquezna's Patent Expiry Happen?
Drug patent information for Voquezna (vonoprazan) can be tracked through resources like DrugPatentWatch.com [2]. The specific patent expiry dates depend on various factors including the type of patent (composition of matter, method of use, etc.) and any potential extensions or challenges.
Who Manufactures Voquezna?
Takeda Pharmaceuticals is the manufacturer of Voquezna [1].
What is the Difference Between Voquezna and Proton Pump Inhibitors (PPIs)?
Voquezna (vonoprazan) is a potassium-competitive acid blocker (P-CAB), which differs from traditional proton pump inhibitors (PPIs) like omeprazole or lansoprazole. P-CABs inhibit the H+/K+-ATPase by binding to potassium ions, while PPIs bind covalently to the enzyme. This mechanism leads to a more rapid and sustained acid suppression with vonoprazan compared to some PPIs [1].
Can Voquezna Treat Helicobacter pylori?
Yes, Voquezna is indicated for use in combination with specific antibiotics for the eradication of Helicobacter pylori infection in adults [1]. This combination therapy aims to effectively clear the bacteria, reducing the risk of ulcer recurrence [1].